ARS Pharma股价暴跌，因其过敏性鼻喷雾剂面临医保报销障碍

路透中文06-25 21:40
BUZZ-ARS Pharma股价暴跌，因其过敏性鼻喷雾剂面临医保报销障碍

6月25日 - ** ARS Pharmaceuticals（SPRY.O）股价下跌26%至7.79美元，结束了连续三天的上涨势头

** ARS制药公司周三晚间 (link) 表示，其过敏喷雾剂“Neffy”在7月的最新审批周期中未获得任何新的保险报销批准

** “Neffy”是一种用于紧急治疗严重过敏反应的肾上腺素鼻喷雾剂，目前已获批用于成人及体重超过一定标准的儿童

** 该公司为控制成本，将2026年的支出预测下调至约2.48亿美元

** 该公司仍预计“Neffy”的销售增长将有助于在2027年实现现金流盈亏平衡

** “尽管鉴于投资者曾预期CVS CVS.N Caremark的报销决定将带来积极催化效应，这一消息可能会被视为略显负面，但我们认为‘Neffy’的长期价值基本完好无损，我们对该股前景仍持乐观态度，”Leerink Partners分析师表示

** 通过现有保险覆盖范围以及价格与其他肾上腺素产品持平的零售现金购买选项，该药物仍可广泛供商业保险患者使用

** 截至上一交易日收盘，该股年内累计下跌9.5%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment